Retrospective Multicenter Observational Study to Evaluate Safety and Effectiveness of Bevacizumab (Avastin) in Combination With Paclitaxel and Cisplatin/Carboplatin or Toptecan in Patients With Advanced Cervical Cancer
Phase of Trial: Phase IV
Latest Information Update: 19 Mar 2018
Price : $35 *
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin; Cisplatin; Paclitaxel; Topotecan
- Indications Cervical cancer
- Focus Adverse reactions
- Sponsors Roche
- 31 Aug 2018 Biomarkers information updated
- 28 Feb 2018 Status changed from recruiting to completed.
- 29 Sep 2017 Planned End Date changed from 1 Sep 2017 to 20 Oct 2017.